Nervenarzt最新文献_第7页

Mitteilungen der DGPPN 09/2024. DGPPN 09/2024 号来函。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 DOI: 10.1007/s00115-024-01741-2

引用次数: 0

[Advance directives and mental disorders: a practice recommendation of the Commission for Ethics and Law of the German Association for Psychiatry, Psychotherapy and Psychosomatics]. [预嘱与精神障碍：德国精神病学、心理治疗和心身医学协会伦理与法律委员会的实践建议]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-05-03 DOI: 10.1007/s00115-024-01662-0

Sabine Müller, Jakov Gather, Euphrosyne Gouzoulis-Mayfrank, Tanja Henking, Matthias Koller, Henning Saß, Tilman Steinert, Thomas Pollmächer

{"title":"[Advance directives and mental disorders: a practice recommendation of the Commission for Ethics and Law of the German Association for Psychiatry, Psychotherapy and Psychosomatics].","authors":"Sabine Müller, Jakov Gather, Euphrosyne Gouzoulis-Mayfrank, Tanja Henking, Matthias Koller, Henning Saß, Tilman Steinert, Thomas Pollmächer","doi":"10.1007/s00115-024-01662-0","DOIUrl":"10.1007/s00115-024-01662-0","url":null,"abstract":"Background: Since the creation of legal requirements for advance directives by the legislator in 2009, special aspects of their application in the treatment of people with mental illnesses have been discussed.Goal of the paper: Important questions on dealing with advance directives in everyday life will be answered in a practice-oriented manner.Results: Among other things, this document answers the question of the conditions under which a patient can refuse or consent to hospitalization and treatment in advance, and in particular how to deal with advance directives whose implementation would also affect the rights of third parties. The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) has addressed these and other questions in the present document and added practical advice on how to formulate advance directives for people with mental illnesses and how to deal with psychiatric advance directives.Discussion: The DGPPN has developed an advance directive for the area of mental health and published it on its website together with detailed explanations. With the help of this advance directive, people can decide on their treatment in phases of incapacity to consent in the context of a mental crisis or illness.","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"861-867"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Cannabis use and cannabis use disorders]. [大麻使用和大麻使用障碍]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI: 10.1007/s00115-024-01722-5

E Hoch, U W Preuss

引用次数: 0

[The challenges for psychiatric care posed by synthetic drugs]. [合成药物给精神病治疗带来的挑战]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-08-26 DOI: 10.1007/s00115-024-01705-6

Norbert Scherbaum, Udo Bonnet

{"title":"[The challenges for psychiatric care posed by synthetic drugs].","authors":"Norbert Scherbaum, Udo Bonnet","doi":"10.1007/s00115-024-01705-6","DOIUrl":"10.1007/s00115-024-01705-6","url":null,"abstract":"Background: In addition to the drugs that have been known for decades, several hundred mainly synthetic substances have been identified as drugs for the first time in the last 20 years.Aim of the work: Presentation of the various groups of substances and their psychotropic effects, the epidemiology of their use and the legal and social background of this development.Material: Narrative literature review.Results: The most important new psychoactive substances (NPS) are synthetic cannabinoids, synthetic stimulants (cathinones), halluginogens and new synthetic opioids (NSO), in particular fentanyl and related substances. The new substances do not have any qualitatively new psychotropic effects. They were brought onto the market in particular as substitutes for substances subject to the Narcotics Act but are often associated with dangerous side effects and even mortality. The increasing availability of these substances has gone hand in hand with the establishment of the Internet as a source of knowledge (e.g. for synthesis routes) and as a marketplace. Substance group-related regulations have also been established in Germany (New Psychoactive Substances Act). In Germany the prevalence of NPS use is significantly lower than that of cannabis; however, there are indications that the production and distribution of synthetic drugs is more profitable for drug dealers than with conventional plant-based drugs, such as heroin. In the USA, for example, NSOs are the primarily drugs used for opioid addiction.Discussion: It remains to be seen whether NPS and NSOs will replace conventional drugs. The availability of synthetic drugs is more difficult to reduce than that of plant-based drugs. Harm reduction measures should be expanded, e.g., early warning systems for new drugs, drug checking and naloxone programs.","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"818-823"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment]. [精神病学中的迷幻剂和解离剂：治疗中的挑战]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-08-28 DOI: 10.1007/s00115-024-01727-0

Johannes Jungwirth, Francesco Bavato, Boris B Quednow

{"title":"[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].","authors":"Johannes Jungwirth, Francesco Bavato, Boris B Quednow","doi":"10.1007/s00115-024-01727-0","DOIUrl":"10.1007/s00115-024-01727-0","url":null,"abstract":"With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of new psychotropic drugs, the psychiatric research into the clinical application of hallucinogens in psychiatry has literally blossomed in the last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic acid diethylamide (LSD) and psilocybin, and dissociative agents, such as ketamine and esketamine, have raised great hopes among researchers, clinicians and patients in recent years, so that there was already talk of a new era in psychiatry. As one of the first of these substances, in December 2019 intranasal esketamine was approved in the USA and the EU for the treatment of treatment-resistant depression and Switzerland followed in 2020. Recently, psilocybin was approved in Australia, Canada and Switzerland for compassionate use in exceptional cases for the treatment of depression, while large approval studies with various psychedelic agents are currently ongoing worldwide. The medical application of psychedelic agents and ketamine/esketamine is considered to be safe; however, as with all new forms of treatment it is of crucial importance that, in addition to the hopes, the specific challenges of these new treatment approaches must also be carefully considered and assessed. Excessive expectations and an insufficient risk-benefit estimation are detrimental to the patients and the reputation of the treating physician. Although a possible paradigm shift in the care of mental health is already being discussed, this review article consciously concentrates on the possible risks of treatment and the methodological weaknesses of the studies carried out so far.","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"803-810"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Psychiatric symptoms of Huntington's disease]. [亨廷顿氏病的精神症状]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.1007/s00115-024-01728-z

Alzbeta Mühlbäck, Rainer Hoffmann, Nicolo Gabriele Pozzi, Martin Marziniak, Peter Brieger, Matthias Dose, Josef Priller

引用次数: 0

[The challenge of drugs: a dynamic situation requires evidence-based interventions]. [毒品的挑战：动态局势需要循证干预]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-09-04 DOI: 10.1007/s00115-024-01724-3

Falk Kiefer

引用次数: 0

[Sexual abuse in the area of responsibility of the Protestant Church: some results from a subproject of the ForuM study]. [新教教会责任区内的性虐待：ForuM 研究子项目的一些结果]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-04-29 DOI: 10.1007/s00115-024-01670-0

Harald Dreßing, Dieter Dölling, Elke Voss, Leonie Scharmann, Andreas Hoell

引用次数: 0

[Individual placement and support in mental health services: evaluation of routine clinical data using a retrospective chart review]. [心理健康服务中的个人安置和支持：利用回顾性病历审查对常规临床数据进行评估]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-07-18 DOI: 10.1007/s00115-024-01706-5

Dorothea Jäckel, Karolina Leopold, Andreas Bechdolf

{"title":"[Individual placement and support in mental health services: evaluation of routine clinical data using a retrospective chart review].","authors":"Dorothea Jäckel, Karolina Leopold, Andreas Bechdolf","doi":"10.1007/s00115-024-01706-5","DOIUrl":"10.1007/s00115-024-01706-5","url":null,"abstract":"Background: People with severe mental illnesses are often excluded from working life and would like support to (re)enter the general labor market as part of the psychiatric treatment. Individual placement and support (IPS) is an effective method of finding and retaining work in the general labor market. The aim of the study was to determine the integration rates of IPS into the general labor market in acute and postacute psychiatric settings, identifying patient, setting and program characteristics associated with (re)entering work.Method: A retrospective chart review (RCR) of routine clinical data between 2016 and 2021 was carried out. The IPS program adherence was rated using the IPS fidelity scale.Results: A total of 375 patients participated in the IPS with at least 4 appointments. The (re)integration rate into the general labor market was 51.7%. A shorter time period to the last working day, diagnosis of F1, F2, F3 (vs. F4), change of treatment setting and IPS in the psychiatric institute outpatient department (PIA), IPS fidelity and the number of IPS coaching sessions were positively correlated with (re)integration into work.Conclusion: The implementation of IPS in clinical mental healthcare is possible and leads to high integration rates in the open labor market. An early start of IPS during the clinical treatment can promote social inclusion.","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"839-844"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11374846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Mentally ill people with means-tested benefits at the job center : Diagnosis spectrum and care-First results from the LIPSY project]. [在就业中心领取经济情况调查津贴的精神病患者：诊断范围和护理--LIPSY 项目的初步结果]。

IF 0.9 4区医学

Nervenarzt Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1007/s00115-024-01723-4

M Koschig, F Hußenöder, I Conrad, M Alberti, K Gatzsche, L Bieler, K Stengler, S G Riedel-Heller

{"title":"[Mentally ill people with means-tested benefits at the job center : Diagnosis spectrum and care-First results from the LIPSY project].","authors":"M Koschig, F Hußenöder, I Conrad, M Alberti, K Gatzsche, L Bieler, K Stengler, S G Riedel-Heller","doi":"10.1007/s00115-024-01723-4","DOIUrl":"10.1007/s00115-024-01723-4","url":null,"abstract":"Background: Although people receiving means-tested benefits are regularly taken care of at the job center, little is known about their mental health situation and mental health care.Objective: The aim of the study was to describe the diagnostic spectrum and the functional status as well as the mental health care utilization of individuals with mental illnesses who are receiving means-tested benefits.Methods: Mentally ill people with means-tested benefits were recruited at the job center as part of the \"Leipzig Individual Placement and Support for Mentally Ill People\" (LIPSY) project, where they were initially diagnosed according to ICD-10 and included in the project if they had a mental disorder. Mental healthcare utilization was recorded. In the present study, data from n = 583 consecutively included persons were analyzed descriptively and by multivariate statistics.Results: Of the study participants 60.7% (n = 583; 51.5% female; average age 36 years; unemployed for an average of 4.8 years) suffered from affective disorders, followed by neurotic, stress and somatoform disorders (42.5%). With a mean global assessment of functioning (GAF) value of 49.4 (SD 7.7), there was on average a serious impairment. Nearly half of the subjects (48.5%) had never received psychotherapeutic, psychiatric or neurological treatment in the 6 months prior to inclusion in the project.Discussion: It could be shown that there is a broad spectrum of mental disorders with substantial functional impairment. The data suggest that this group is significantly undertreated and difficult to reach.","PeriodicalId":49770,"journal":{"name":"Nervenarzt","volume":" ","pages":"845-852"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0